{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:02:06Z","timestamp":1791302526290,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.nbd.2007.07.028","type":"journal-article","created":{"date-parts":[[2007,8,20]],"date-time":"2007-08-20T12:45:21Z","timestamp":1187613921000},"page":"22-29","source":"Crossref","is-referenced-by-count":51,"title":["Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo"],"prefix":"10.1016","volume":"29","author":[{"given":"Delphine","family":"Charvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Roze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Deyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Betuing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"R\u00e9gulier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Luthi-Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Brouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"D\u00e9glon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyne","family":"Caboche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2007.07.028_bib1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.1085","article-title":"Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington\u2019s disease","volume":"50","author":"Andreassen","year":"2001","journal-title":"Ann. Neurol."},{"issue":"Pt 12","key":"10.1016\/j.nbd.2007.07.028_bib2","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","article-title":"Huntington\u2019s disease progression. PET and clinical observations","volume":"122","author":"Andrews","year":"1999","journal-title":"Brain"},{"issue":"Pt 6","key":"10.1016\/j.nbd.2007.07.028_bib3","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington\u2019s disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2007.07.028_bib4","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2007.07.028_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1212\/WNL.44.5.823","article-title":"Reduced basal ganglia volume associated with the gene for Huntington\u2019s disease in asymptomatic at-risk persons","volume":"44","author":"Aylward","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2007.07.028_bib6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archneur.1996.00550120105023","article-title":"Basal ganglia volume and proximity to onset in presymptomatic Huntington disease","volume":"53","author":"Aylward","year":"1996","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.nbd.2007.07.028_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P","article-title":"Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington\u2019s disease","volume":"15","author":"Aylward","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2007.07.028_bib8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/01.WNL.0000132965.14653.D1","article-title":"Onset and rate of striatal atrophy in preclinical Huntington disease","volume":"63","author":"Aylward","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2007.07.028_bib9","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1073\/pnas.120166397","article-title":"Severe deficiencies in dopamine signaling in presymptomatic Huntington\u2019s disease mice","volume":"97","author":"Bibb","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2007.07.028_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00004850-200403000-00001","article-title":"Huntington\u2019s disease: present treatments and future therapeutic modalities","volume":"19","author":"Bonelli","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.nbd.2007.07.028_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-8993(95)01417-9","article-title":"Parenterally administered 3-nitropropionic acid and amphetamine can combine to produce damage to terminals and cell bodies in the striatum","volume":"712","author":"Bowyer","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2007.07.028_bib12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.npp.1300874","article-title":"Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels","volume":"31","author":"Bustillo","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nbd.2007.07.028_bib13","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1523\/JNEUROSCI.1197-04.2004","article-title":"Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington\u2019s disease","volume":"24","author":"Canals","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2007.07.028_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-3565(24)36396-7","article-title":"Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine","volume":"280","author":"Cass","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2007.07.028_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neuroscience.2004.07.043","article-title":"Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum","volume":"129","author":"Centonze","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2007.07.028_bib16","doi-asserted-by":"crossref","first-page":"12218","DOI":"10.1073\/pnas.0502698102","article-title":"Unraveling a role for dopamine in Huntington\u2019s disease: the dual role of reactive oxygen species and D2 receptor stimulation","volume":"102","author":"Charvin","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2007.07.028_bib17","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1460-9568.2005.03985.x","article-title":"Akt is altered in an animal model of Huntington\u2019s disease and in patients","volume":"21","author":"Colin","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2007.07.028_bib18","doi-asserted-by":"crossref","first-page":"11035","DOI":"10.1073\/pnas.1831768100","article-title":"Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons","volume":"100","author":"Cyr","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2007.07.028_bib19","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1096\/fj.06-6533fje","article-title":"Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin","volume":"20","author":"Cyr","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.nbd.2007.07.028_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2007.07.028_bib21","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1523\/JNEUROSCI.22-09-03473.2002","article-title":"Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length","volume":"22","author":"de Almeida","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2007.07.028_bib22","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1471-4159.2003.01706.x","article-title":"Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington\u2019s disease transgenic mice","volume":"85","author":"Dedeoglu","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2007.07.028_bib23","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.nbd.2007.07.028_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.870100213","article-title":"Functional decline in Huntington\u2019s disease","volume":"10","author":"Feigin","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2007.07.028_bib25","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemoterapy ameliorates the neurodegenerative phenotype in Huntington\u2019s Disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2007.07.028_bib27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2007.07.028_bib28","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ana.410280503","article-title":"A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington\u2019s disease","volume":"28","author":"Grafton","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2007.07.028_bib29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes","volume":"72","author":"Group","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2007.07.028_bib30","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","article-title":"Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology","volume":"19","author":"Gutekunst","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2007.07.028_bib31","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2007.07.028_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1471-4159.2005.03348.x","article-title":"Purification of neuronal inclusions of patients with Huntington\u2019s disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers","volume":"95","author":"Hoffner","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2007.07.028_bib34","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1073\/pnas.162362299","article-title":"Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington\u2019s disease","volume":"99","author":"Keene","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2007.07.028_bib35","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1073\/pnas.0400243101","article-title":"Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington\u2019s disease","volume":"101","author":"Lee","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2007.07.028_bib36","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/hmg\/8.7.1227","article-title":"Ultrastructural localization and progressive formation of neuropil aggregates in Huntington\u2019s disease transgenic mice","volume":"8","author":"Li","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2007.07.028_bib37","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1074\/jbc.273.6.3756","article-title":"Dopamine induces apoptosis through an oxidation-involved SAPK\/JNK activation pathway","volume":"273","author":"Luo","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2007.07.028_bib38","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/hmg\/9.9.1259","article-title":"Decreased expression of striatal signaling genes in a mouse model of Huntington\u2019s disease","volume":"9","author":"Luthi-Carter","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2007.07.028_bib39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2007.07.028_bib40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM198702123160701","article-title":"Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington\u2019s disease","volume":"316","author":"Mazziotta","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2007.07.028_bib42","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1006\/exnr.1999.7327","article-title":"Decrease in striatal enkephalin mRNA in mouse models of Huntington\u2019s disease","volume":"162","author":"Menalled","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2007.07.028_bib43","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/archneur.1991.00530200036015","article-title":"Factors associated with slow progression in Huntington\u2019s disease","volume":"48","author":"Myers","year":"1991","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.nbd.2007.07.028_bib44","doi-asserted-by":"crossref","first-page":"11840","DOI":"10.1073\/pnas.0502177102","article-title":"Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington\u2019s disease mouse model","volume":"102","author":"Nguyen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2007.07.028_bib46","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archpsyc.1997.01830220079011","article-title":"Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings","volume":"54","author":"Nyberg","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.nbd.2007.07.028_bib47","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1523\/JNEUROSCI.3706-05.2006","article-title":"Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421","volume":"26","author":"Pardo","year":"2006","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.nbd.2007.07.028_bib48","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/mt.sj.6300141","article-title":"Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington\u2019s disease","volume":"15","author":"Perrin","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2007.07.028_bib49","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s004150050272","article-title":"Huntington\u2019s disease and other choreas","volume":"245","author":"Quinn","year":"1998","journal-title":"J. Neurol."},{"key":"10.1016\/j.nbd.2007.07.028_bib50","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/hmg\/ddg305","article-title":"Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum","volume":"12","author":"Regulier","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2007.07.028_bib51","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2007.07.028_bib52","doi-asserted-by":"crossref","first-page":"10116","DOI":"10.1523\/JNEUROSCI.18-23-10116.1998","article-title":"Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington\u2019s disease","volume":"18","author":"Reynolds","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2007.07.028_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0006-8993(82)90198-6","article-title":"Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain","volume":"235","author":"Ricaurte","year":"1982","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2007.07.028_bib54","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/01.WNL.0000065888.88988.6E","article-title":"Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis","volume":"60","author":"Rosas","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2007.07.028_bib55","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature01301","article-title":"Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders","volume":"421","author":"Sanchez","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2007.07.028_bib56","doi-asserted-by":"crossref","first-page":"11402","DOI":"10.1073\/pnas.0503634102","article-title":"Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions","volume":"102","author":"Slow","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2007.07.028_bib58","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm985","article-title":"Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease","volume":"10","author":"Tanaka","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2007.07.028_bib60","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1097\/00001756-200011270-00032","article-title":"N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington\u2019s disease mice","volume":"11","author":"van Dellen","year":"2000","journal-title":"NeuroReport"},{"key":"10.1016\/j.nbd.2007.07.028_bib61","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2007.07.028_bib62","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington\u2019s disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2007.07.028_bib63","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1073\/pnas.88.5.1859","article-title":"D1 and D2 dopamine receptor mRNA in rat brain","volume":"88","author":"Weiner","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996107001738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996107001738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T13:41:33Z","timestamp":1737380493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996107001738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0969996107001738"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2007.07.028","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}